More Botanix Pharmaceuticals Limited news
Botanix Pharmaceuticals LimitedASX: BOT

Study Confirms Anti-inflammatory and Other Properties of CBD

Jun 18, 2019 at 11:52 PM EDT · Issued by Botanix Pharmaceuticals Limited

Filed with ASX · Jun 18, 2019 at 11:52 PM EDT · 5 pages · English

On 6ix: 6ix.com/news/study-confirms-anti-inflammatory-and-other-properties-of-cbd

Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2↗

Botanix Pharmaceuticals Limited on 6ix

In the deck

  • Botanix Pharmaceuticals — Investor Presentation (June 2019)36 slidesJun 20, 2019

Story so far

  • Permetrex Outperforms Other CBD Topical ProductsFeb 26, 2019

Earlier from Botanix Pharmaceuticals

  • Pause in TradeJun 17, 2019
  • Dermatology Industry Leader Joins BotanixMay 19, 2019
  • Botanix Provides Retraction in PresentationMay 16, 2019
  • Pause In TradingMay 15, 2019
  • Permetrex Outperforms Other CBD Topical ProductsFeb 25, 2019

Later from Botanix Pharmaceuticals

  • BTX 1801 Kills Superbugs Without Resistance World-FirstJun 19, 2019
  • Botanix Antimicrobial Platform Addresses Global ThreatJul 14, 2019
  • Botanix $40 Million US Lead Placement and Management UpdateJul 31, 2019
  • Appendix 4E and Annual ReportAug 19, 2019
  • Botanix announces new clinical program to target rosaceaSep 15, 2019
All Botanix Pharmaceuticals news releases↗

Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.

Follow Botanix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer